Citius Pharmaceuticals Inc Stock

$0.13

0.22% yesterday

Nasdaq, Nov 25, 10:16 pm CET

ISIN

US17322U2078

Symbol

CTXR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Citius Pharmaceuticals Inc Stock price

$0.13

-0.33 70.98% 5Y

Nasdaq, Closing price Mon, Nov 25 2024

-0.00 0.22%

ISIN

US17322U2078

Symbol

CTXR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$644.74m
Enterprise Value	$627.75m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	7.04
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-41.07m
Free Cash Flow (TTM) Free Cash Flow	$-29.09m
Cash position	$17.91m
EPS (TTM) EPS	$-0.24
P/E forward	negative
Short interest	7.00%

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Get Started for Free Today

Citius Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

??

3 Analysts have issued a Citius Pharmaceuticals Inc forecast:

2x Buy

67%

1x Hold

33%

More details on Analyst Estimates Including Price Targets

3 Analysts have issued a Citius Pharmaceuticals Inc forecast:

Buy

67%

Hold

33%

Analyst Estimates with Stock Price Targets

Financial data from Citius Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.21 0.21	11% 11% -
Gross Profit	-0.21 -0.21	11% 11% -
- Selling and Administrative Expenses	29 29	60% 60% -
- Research and Development Expense	12 12	25% 25% -
EBITDA	-41 -41	20% 20% -
- Depreciation and Amortization	0.21 0.21	11% 11% -
EBIT (Operating Income) EBIT	-41 -41	20% 20% -
Net Profit	-38 -38	25% 25% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Citius Pharmaceuticals Inc Stock News

Neutral

PRNewsWire

●

about 24 hours ago

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

CRANFORD, N.J. , Nov. 25, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that the Company held a constructive in-person Type C meeting with the U.S. Food and Drug Administration (FDA).

Neutral

PRNewsWire

●

4 days ago

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split

CRANFORD, N.J. , Nov. 22, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) announced today that it will be executing a reverse stock split of its common stock, par value $0.001 per share, at a ratio of 1-for-25 ("Reverse Stock Split").

Neutral

PRNewsWire

●

8 days ago

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering

CRANFORD, N.J. , Nov. 18, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today closed its previously announced registered direct offering for the purchase of an aggregate of 12,000,000 shares of its common stock and accompa...

More Citius Pharmaceuticals Inc News

Company Profile

Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

Head office	United States
CEO	Leonard Mazur
Employees	22
Founded	2007
Website	www.citiuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now